Best practices for the Multidisciplinary Management of NHL using Antibody Therapeutics
Podcast
Pre-test

Questions marked with a * are required

100%

Contact Information

First Name

Last Name

Email Address

Geoffrey is a 69-year-old man who you previously diagnosed as having stage IV non-GCB DLBCL with an IPI of 4. You administered three cycles of R-CHOP, noting slowly responsive disease on CT, whereupon you administered three more cycles of R-CHOP. Repeat biopsy, however, confirmed primary refractory disease. As second-line therapy, you then prescribed two cycles of polatuzumab vedotin and rituximab as bridging treatment for Geoffrey, followed by fludarabine/cyclophosphamide lymphodepletion and CD19-directed CAR T-cell treatment with axi-cel. Geoffrey continues to progress. What is the next best step for this patient?

Chemotherapy and autologous transplant

Involved field radiation

Glofitamab

Mosunetuzumab

Which of the following statements best describes the findings of the phase 2 LOTIS-2 trial investigating loncastuximab tesirine in patients with R/R DLBCL?

The most common treatment-emergent adverse event was nausea

More than one-fourth of patients achieved a complete response

Patients with double-hit DLBCL were not included in the study

Nearly half of patients who achieved complete response were event free for ≥1 year